Proteins, protein fragments, nucleic acids and vectors derived from Neisseria gonorrhoeae, as well as to methods of inducing immunity against N. gonorrhoeae. Also disclosed are antibodies binding to the proteins and protein fragments.
C07K 14/22 - Peptides having more than 20 amino acidsGastrinsSomatostatinsMelanotropinsDerivatives thereof from bacteria from Neisseriaceae (F), e.g. Acinetobacter
C12N 15/74 - Vectors or expression systems specially adapted for prokaryotic hosts other than E. coli, e.g. Lactobacillus, Micromonospora
2.
Proteins and nucleic acids useful in vaccines targeting Pseudomonas aeruginosa
Disclosed are immunogenic proteins from Pseudomonas aeruginosa as well as nucleic acids, vectors and transformd cells useful for expression of the proteins. Also disclosed are methods for prophylaxis of infection with Pseudomonas aeruginosa using the proteins, nucleic acids, vectors or transformed cells.
A61K 47/64 - Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
The present invention relates to proteins and nucleic acids derived from Staphylococcus aureus as well as therapeutic and diagnostic uses of the proteins and nucleic acids.
C07K 14/31 - Peptides having more than 20 amino acidsGastrinsSomatostatinsMelanotropinsDerivatives thereof from bacteria from Micrococcaceae (F) from Staphylococcus (G)
C07K 16/12 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against material from bacteria
C12Q 1/689 - Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for detection or identification of organisms for bacteria
G01N 33/569 - ImmunoassayBiospecific binding assayMaterials therefor for microorganisms, e.g. protozoa, bacteria, viruses
4.
PEPTIDES DERIVED FROM ACINETOBACTER BAUMANNII AND THEIR USE IN VACCINATION
The present invention relates to proteins derived from Acinetobacter baumanii, nucleic acids encoding the proteins, antibodies specific for the proteins as well as methods of therapy, prophylaxis, and diagnosis that utilise the proteins, nucleic acids, and antibodies.
The disclosure provides a novel process for producing a synthetic circular DNA (scDNA) molecule and a novel scDNA molecule which can be produced by the method. The disclosure further provides therapeutical methods using the scDNA molecule.
Immunogenic proteins from Pseudomonas aeruginosa as well as nucleic acids, vectors and transformed cells useful for expression of the proteins. Also disclosed are methods for prophylaxis of infection with Pseudomonas aeruginosa using the proteins, nucleic acids, vectors or transformed cel
C07K 14/33 - Peptides having more than 20 amino acidsGastrinsSomatostatinsMelanotropinsDerivatives thereof from bacteria from Clostridium (G)
C07K 14/34 - Peptides having more than 20 amino acidsGastrinsSomatostatinsMelanotropinsDerivatives thereof from bacteria from Corynebacterium (G)
C07K 14/435 - Peptides having more than 20 amino acidsGastrinsSomatostatinsMelanotropinsDerivatives thereof from animalsPeptides having more than 20 amino acidsGastrinsSomatostatinsMelanotropinsDerivatives thereof from humans
C07K 16/12 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against material from bacteria
C12Q 1/689 - Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for detection or identification of organisms for bacteria
G01N 33/569 - ImmunoassayBiospecific binding assayMaterials therefor for microorganisms, e.g. protozoa, bacteria, viruses
Immune therapy and vaccines, such as cancer immunotherapy, or vaccines for infections with microorganisms, such as a bacterial or viral infection. In particular, the present invention relates to methods and products for prophylactic or treating cancer or infections with microorganisms by administration of specific fusion polypeptides or nucleic acids encoding such fusion polypeptides.
The present application discloses novel polypeptides, polynucleotides, expression vectors and novel immunogenic compositions derived from Staphylococcus aureus, in particular novel polypeptides, polynucleotides, expression vectors and compositions derived from/related to the SpA, Hla, Aur and LukE polypeptides. Also disclosed is methods of immunity induction utilising the polypeptides, polynucleotides, expression vectors, and immunogenic compositions.
C07K 14/31 - Peptides having more than 20 amino acidsGastrinsSomatostatinsMelanotropinsDerivatives thereof from bacteria from Micrococcaceae (F) from Staphylococcus (G)
9.
Process for preparation of neopepitope-containing vaccine agents
The present invention presents an improved method for identification of neoepitopes useful in active immunotherapy targeting malignant neoplasms. The method integrates identification of somatic variants of expression product with a balanced evaluation of such variants' 1) ability to bind MHC, 2) ability to induce immune responses, 3) clonal coverage in the tumour tissue, and 4) ability to evade immune responses. Also, the method is complemented by a method for purposive deselection of neoepitopes that could induced undesired immune response against normal cells. Also disclosed is a method for preparing immunogenic compositions, a method for treatment of cancer, and a computer system for identifying neoepitopes and neopeptides
G16H 50/30 - ICT specially adapted for medical diagnosis, medical simulation or medical data miningICT specially adapted for detecting, monitoring or modelling epidemics or pandemics for calculating health indicesICT specially adapted for medical diagnosis, medical simulation or medical data miningICT specially adapted for detecting, monitoring or modelling epidemics or pandemics for individual health risk assessment
10.
PERSONALIZED CANCER THERAPY TARGETING NORMALLY NON-EXPRESSED SEQUENCES
Provided is a method for identifying immunogenic amino acid sequences in a sample of malignant tissue from a patient comprising A) determining amino acid sequences of proteinaceous expression products from the malignant tissue,B) analysing said amino acid sequences to identify therein proteinaceous expression products of selected genomic sequences in the patient's species, C) identifying - in the proteinaceous expression products ? the amino acid sequences, which are those that will bind to MHC molecules of the patient,where said selected genomic sequences constitute a subset of all sequences of the genome of said species and where said subset is constituted by sequences, which encode proteinaceous expression products in at most 5% of samples from any healthy tissue, where said healthy tissue is a tissue of a type found in the patient, and where said healthy tissue optionally does not include testis tissue and/or brain tissue. Also, a related method for treatment of cancer is provided as well as a computer system.In addition is provided a method for stratifying cancer patients into groups of those eligible for immunotherapy or not, based on their burden of expression of endogenous retrovirus.
Provided is a method for identifying immunogenic amino acid sequences in a sample of malignant tissue from a patient comprising A) determining amino acid sequences of proteinaceous expression products from the malignant tissue,B) analysing said amino acid sequences to identify therein proteinaceous expression products of selected genomic sequences in the patient's species, C) identifying - in the proteinaceous expression products – the amino acid sequences, which are those that will bind to MHC molecules of the patient,where said selected genomic sequences constitute a subset of all sequences of the genome of said species and where said subset is constituted by sequences, which encode proteinaceous expression products in at most 5% of samples from any healthy tissue, where said healthy tissue is a tissue of a type found in the patient, and where said healthy tissue optionally does not include testis tissue and/or brain tissue. Also, a related method for treatment of cancer is provided as well as a computer system.In addition is provided a method for stratifying cancer patients into groups of those eligible for immunotherapy or not, based on their burden of expression of endogenous retrovirus.
The present invention relates to cancer therapy, in particular cancer immunotherapy. In particular, the present invention relates to methods and products for treating cancer by administration of specific fusion polypeptides or nucleic acids encoding such fusion polypeptides.
C07K 16/28 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
C07K 14/78 - Connective tissue peptides, e.g. collagen, elastin, laminin, fibronectin, vitronectin or cold insoluble globulin [CIG]
C07K 14/47 - Peptides having more than 20 amino acidsGastrinsSomatostatinsMelanotropinsDerivatives thereof from animalsPeptides having more than 20 amino acidsGastrinsSomatostatinsMelanotropinsDerivatives thereof from humans from vertebrates from mammals
Proteins, protein fragments, nucleic acids and vectors derived from Neisseria gonorrhoeae, as well as to methods of inducing immunity against N. gonorrhoeae. Also disclosed are antibodies binding to the proteins and protein fragments.
Disclosed is chimeric polypeptides derived from S. aureus proteins having SEQ ID NOs: 1-9 and 139-146. The chimeric polypeptides are useful as immunogens for providing protective immunity against S. aureus infection. Also disclosed are compositions, methods of treatment and prophylaxis, nucleic acids and vectors comprising the nucleic acids.
C07K 14/31 - Peptides having more than 20 amino acidsGastrinsSomatostatinsMelanotropinsDerivatives thereof from bacteria from Micrococcaceae (F) from Staphylococcus (G)
The present invention relates to proteins, protein fragments, nucleic acids and vectors derived from Neisseria gonorrhoeae, as well as to methods of inducing immunity against N. gonorrhoeae. Also disclosed are antibodies binding to the proteins and protein fragments.
C07K 14/22 - Peptides having more than 20 amino acidsGastrinsSomatostatinsMelanotropinsDerivatives thereof from bacteria from Neisseriaceae (F), e.g. Acinetobacter
The present invention relates to proteins, protein fragments, nucleic acids and vectors derived from Neisseria gonorrhoeae, as well as to methods of inducing immunity against N. gonorrhoeae. Also disclosed are antibodies binding to the proteins and protein fragments.
C07K 14/22 - Peptides having more than 20 amino acidsGastrinsSomatostatinsMelanotropinsDerivatives thereof from bacteria from Neisseriaceae (F), e.g. Acinetobacter
17.
METHOD FOR PREDICTING RESPONSE TO CANCER IMMUNOTHERAPY
The present invention relates to method for predicting patient responses to cancer immunotherapy, in particular treatment with immune checkpoint inhibitors and/or treatment involving induction of specific antitumour immunity. The method comprises quantitively determining the expression levels of MHC Class I and II molecule isotypes by the cells of the microenvironment of the patient's malignant neoplasm and calculating a combined expression score value from weighted expression levels of at least HLA-A, -B, -C, -DR isotypes. Also provided are methods of treatment and determination of eligibility for treatment.
C12Q 1/6886 - Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
Provided are novel fusion polypeptides comprising a B-cell epitope-rich region, which comprises at least one fragment of at least one surface exposed protein from an intracellular pathogen, and a T-cell epitope-rich region, which comprises at least 2 densely arranged groups of T-cell epitope hotspots comprising at least one CTL inducing amino acid sequence, where the epitope hotspots are derived from at least two non-identical proteins of said intracellular pathogen. Also disclosed are nucleic acids and vectors encoding the fusion polypeptides and pharmaceutical means and methods based on the fusion polypeptides, nucleic acids and vectors.
A method for T-cell epitope prediction where quantitative scores of stability in the binding between peptides and MHC molecules are integrated into the derivation of the likelihood that a peptide of defined amino acid sequence constitutes a T-cell epitope. Preferably, stability data are obtained an MS-based method for identification of MHC binding peptides, where the binding capability is quantitatively assessed to allow distinction between stably binding peptides and peptides that are unlikely to be presented to T-cells. The method includes a step of time-course or thermostability testing of naturally processed peptides bound to MHC. Also disclosed are methods for preparation of personalized immunogenic compositions, methods of therapeutic treatment of malignancies, and a computer system that implements the T-cell epitope prediction method.
05 - Pharmaceutical, veterinary and sanitary products
09 - Scientific and electric apparatus and instruments
42 - Scientific, technological and industrial services, research and design
Goods & Services
Pharmaceuticals and medical preparations; medicine for
treatment of cancer; pharmaceuticals preparations and
substances for the treatment of cancer, viral diseases,
allergy, autoimmune diseases, microbiota dysbiosis and
parasites; biopharmaceuticals for the treatment of cancer,
viral diseases, allergy, autoimmune diseases, microbiota
dysbiosis and parasites; preparations for immunotherapy;
antibodies; vaccines for human use; viral vaccines; vaccine
adjuvants; cells for medical use. Software; software based on artificial intelligence;
artificial intelligence and machine learning software;
platforms for artificial intelligence; software for the
treatment of cancer; software for design and development of
immunotherapy; software and software based on artificial
intelligence for identification of antigens and epitopes;
software and software based on artificial intelligence for
design and development of vaccines and medicines; software
and software based on artificial intelligence for the
treatment of cancer, viral diseases, allergy, autoimmune
diseases, microbiota dysbiosis and parasites. Scientific and technological research and services; research
and development services in the field of immunology and
oncology, decoding of data; research and development of
pharmaceuticals; medical and pharmacological research
services; basic and clinical research in the field of
science and medicine; research and development of vaccines
and medicines; scientific and technological research
relating to virus, oncology, and autoimmune diseases,
scientific and technological research relating to allergies;
blood processing, namely the blood process of patients'
blood to isolate lymphocytes for the use in immunotherapy
for therapeutic medical research.
21.
Nucleic acid vaccination using neo-epitope encoding constructs
Compositions and methods for DNA vaccination that target cancer. The method for anti-cancer vaccination using a plasmid based vaccine comprises regions encoding neo-epitopes and comprising amphiphilic block copolymers such as poloxamer and poloxamine agents.
Immunogenic proteins from nontypable Haemophilus influenzae as well as nucleic acids, vectors and transformed cells useful for expression of the proteins. Methods for prophylaxis of infection with nontypable Haemophilus influenzae using the proteins, nucleic acids, vectors or transformed cells.
C07K 14/285 - Peptides having more than 20 amino acidsGastrinsSomatostatinsMelanotropinsDerivatives thereof from bacteria from Pasteurellaceae (F), e.g. Haemophilus influenza
A61K 39/39 - Medicinal preparations containing antigens or antibodies characterised by the immunostimulating additives, e.g. chemical adjuvants
A61K 47/64 - Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
05 - Pharmaceutical, veterinary and sanitary products
09 - Scientific and electric apparatus and instruments
42 - Scientific, technological and industrial services, research and design
Goods & Services
Pharmaceuticals and medical preparations for treating cancer and infectious diseases; medicine for treatment of cancer; pharmaceuticals preparations and substances for the treatment of cancer, viral diseases, allergy, autoimmune diseases, microbiota dysbiosis, and parasites; biopharmaceuticals for the treatment of cancer, viral diseases, allergy, autoimmune diseases, microbiota dysbiosis, and parasites; immunotherapy preparations for treating cancer and infectious diseases; monoclonal antibodies (mAb) for medical purposes; vaccines for human use; viral vaccines; vaccine adjuvants; cells for medical use Downloadable software for design of pharmaceuticals; downloadable artificial intelligence software for design of pharmaceuticals; downloadable artificial intelligence and machine learning software for design of pharmaceuticals; downloadable artificial intelligence software platforms for design of pharmaceuticals; downloadable software for evaluating medical treatment options and treatment outcomes for cancer; downloadable software for design and development of immunotherapy; downloadable software and downloadable artificial intelligence software for identifying antigens and epitopes; downloadable software and downloadable artificial intelligence software for designing and developing vaccines and medicines; downloadable software and downloadable artificial intelligence software for designing pharmaceuticals for cancer, viral diseases, allergy, autoimmune diseases, microbiota dysbiosis and parasites Scientific and technological research services in the field of oncology, infectious diseases, and immunology; scientific research and development services in the fields of immunology and oncology; decoding of data; research and development of pharmaceuticals; medical and pharmacological research services; clinical medical research in the field of oncology, infectious diseases, and immunology; research and development of vaccines and medicines; scientific and technological research relating to virus, oncology, and autoimmune diseases; scientific and technological research relating to allergies
25.
PROCESS FOR PREPARATION OF NEOPEPITOPE-CONTAINING VACCINE AGENTS
The present invention presents an improved method for identification of neoepitopes useful in active immunotherapy targeting malignant neoplasms. The method integrates identification of somatic variants of expression product with a balanced evaluation of such variants' 1) ability to bind MHC, 2) ability to induce immune responses, 3) clonal coverage in the tumour tissue, and 4) ability to evade immune responses. Also, the method is complemented by a method for purposive deselection of neoepitopes that could induced undesired immune response against normal cells. Also disclosed is a method for preparing immunogenic compositions, a method for treatment of cancer, and a computer system for identifying neoepitopes and neopeptides.
The present invention presents an improved method for identification of neoepitopes useful in active immunotherapy targeting malignant neoplasms. The method integrates identification of somatic variants of expression product with a balanced evaluation of such variants' 1) ability to bind MHC, 2) ability to induce immune responses, 3) clonal coverage in the tumour tissue, and 4) ability to evade immune responses. Also, the method is complemented by a method for purposive deselection of neoepitopes that could induced undesired immune response against normal cells. Also disclosed is a method for preparing immunogenic compositions, a method for treatment of cancer, and a computer system for identifying neoepitopes and neopeptides.
The present invention relates to immune therapy and vaccines, such as cancer immunotherapy, or vaccines for infections with microorganisms, such as a bacterial or viral infection. In particular, the present invention relates to methods and products for prophylactic or treating cancer or infections with microorganisms by administration of specific fusion polypeptides or nucleic acids encoding such fusion polypeptides.
The present invention relates to immune therapy and vaccines, such as cancer immunotherapy, or vaccines for infections with microorganisms, such as a bacterial or viral infection. In particular, the present invention relates to methods and products for prophylactic or treating cancer or infections with microorganisms by administration of specific fusion polypeptides or nucleic acids encoding such fusion polypeptides.
Disclosed are novel immunogenic proteins derived from Staphylococcus aureus, as well as methods for their use in conferring protective immunity against S. aureus infections. Also disclosed are nucleic acids encoding the proteins and methods of use of these nucleic acids.
C07K 16/12 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against material from bacteria
C12Q 1/689 - Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for detection or identification of organisms for bacteria
C07K 14/31 - Peptides having more than 20 amino acidsGastrinsSomatostatinsMelanotropinsDerivatives thereof from bacteria from Micrococcaceae (F) from Staphylococcus (G)
The present invention relates to cancer therapy, in particular cancer immunotherapy. In particular, the present invention relates to methods and products for treating cancer by administration of specific fusion polypeptides or nucleic acids encoding such fusion polypeptides.
A61K 39/385 - Haptens or antigens, bound to carriers
C12N 15/117 - Nucleic acids having immunomodulatory properties, e.g. containing CpG-motifs
A61K 47/64 - Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
A61K 31/711 - Natural deoxyribonucleic acids, i.e. containing only 2'-deoxyriboses attached to adenine, guanine, cytosine or thymine and having 3'-5' phosphodiester links
A61K 38/17 - Peptides having more than 20 amino acidsGastrinsSomatostatinsMelanotropinsDerivatives thereof from animalsPeptides having more than 20 amino acidsGastrinsSomatostatinsMelanotropinsDerivatives thereof from humans
A61K 39/00 - Medicinal preparations containing antigens or antibodies
A61K 48/00 - Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseasesGene therapy
The present invention relates to cancer therapy, in particular cancer immunotherapy. In particular, the present invention relates to methods and products for treating cancer by administration of specific fusion polypeptides or nucleic acids encoding such fusion polypeptides.
The disclosure provides novel means and methods for DNA vaccination that targets cancer. In particular is provided a method for anti-cancer vaccination using a plasmid-based vaccine comprising regions encoding neo-epitopes.
C07K 14/31 - Peptides having more than 20 amino acidsGastrinsSomatostatinsMelanotropinsDerivatives thereof from bacteria from Micrococcaceae (F) from Staphylococcus (G)
C12Q 1/68 - Measuring or testing processes involving enzymes, nucleic acids or microorganismsCompositions thereforProcesses of preparing such compositions involving nucleic acids
C07K 16/12 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against material from bacteria
C12Q 1/689 - Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for detection or identification of organisms for bacteria
A61K 39/00 - Medicinal preparations containing antigens or antibodies
34.
NUCLEIC ACID VACCINATION USING NEO-EPITOPE ENCODING CONSTRUCTS
The disclosure provides means and methods for DNA vaccination that target cancer. In particular is provided a method for anti-cancer vaccination using a plasmid based vaccine comprising regions encoding neo-epitopes and comprising amphiphilic block copolymers such as poloxamer and poloxamine agents.
The present invention provides methods of vaccination utilising a cationic liposomal adjuvant admixed with at least one neoepitope and a solvent. Also provided are unit dosages and compositions for use in the methods.
C07K 14/31 - Peptides having more than 20 amino acidsGastrinsSomatostatinsMelanotropinsDerivatives thereof from bacteria from Micrococcaceae (F) from Staphylococcus (G)
C07K 16/12 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against material from bacteria
C12Q 1/689 - Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for detection or identification of organisms for bacteria
G01N 33/569 - ImmunoassayBiospecific binding assayMaterials therefor for microorganisms, e.g. protozoa, bacteria, viruses
A61K 39/00 - Medicinal preparations containing antigens or antibodies
C07K 14/33 - Peptides having more than 20 amino acidsGastrinsSomatostatinsMelanotropinsDerivatives thereof from bacteria from Clostridium (G)
C07K 14/34 - Peptides having more than 20 amino acidsGastrinsSomatostatinsMelanotropinsDerivatives thereof from bacteria from Corynebacterium (G)
C07K 14/435 - Peptides having more than 20 amino acidsGastrinsSomatostatinsMelanotropinsDerivatives thereof from animalsPeptides having more than 20 amino acidsGastrinsSomatostatinsMelanotropinsDerivatives thereof from humans
C07K 16/12 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against material from bacteria
C12Q 1/689 - Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for detection or identification of organisms for bacteria
G01N 33/569 - ImmunoassayBiospecific binding assayMaterials therefor for microorganisms, e.g. protozoa, bacteria, viruses
A61K 39/00 - Medicinal preparations containing antigens or antibodies
A61K 39/00 - Medicinal preparations containing antigens or antibodies
C07K 14/31 - Peptides having more than 20 amino acidsGastrinsSomatostatinsMelanotropinsDerivatives thereof from bacteria from Micrococcaceae (F) from Staphylococcus (G)
C07K 14/31 - Peptides having more than 20 amino acidsGastrinsSomatostatinsMelanotropinsDerivatives thereof from bacteria from Micrococcaceae (F) from Staphylococcus (G)
C07K 14/31 - Peptides having more than 20 amino acidsGastrinsSomatostatinsMelanotropinsDerivatives thereof from bacteria from Micrococcaceae (F) from Staphylococcus (G)
C12Q 1/68 - Measuring or testing processes involving enzymes, nucleic acids or microorganismsCompositions thereforProcesses of preparing such compositions involving nucleic acids
C07K 16/12 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against material from bacteria
C12Q 1/689 - Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for detection or identification of organisms for bacteria
A61K 39/00 - Medicinal preparations containing antigens or antibodies
C07K 14/31 - Peptides having more than 20 amino acidsGastrinsSomatostatinsMelanotropinsDerivatives thereof from bacteria from Micrococcaceae (F) from Staphylococcus (G)
C12Q 1/68 - Measuring or testing processes involving enzymes, nucleic acids or microorganismsCompositions thereforProcesses of preparing such compositions involving nucleic acids
A61K 39/00 - Medicinal preparations containing antigens or antibodies
C12Q 1/689 - Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for detection or identification of organisms for bacteria
C07K 14/31 - Peptides having more than 20 amino acidsGastrinsSomatostatinsMelanotropinsDerivatives thereof from bacteria from Micrococcaceae (F) from Staphylococcus (G)
C07K 16/12 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against material from bacteria
C12Q 1/68 - Measuring or testing processes involving enzymes, nucleic acids or microorganismsCompositions thereforProcesses of preparing such compositions involving nucleic acids
A61K 39/00 - Medicinal preparations containing antigens or antibodies
C07K 14/31 - Peptides having more than 20 amino acidsGastrinsSomatostatinsMelanotropinsDerivatives thereof from bacteria from Micrococcaceae (F) from Staphylococcus (G)
C07K 7/00 - Peptides having 5 to 20 amino acids in a fully defined sequenceDerivatives thereof
C12Q 1/68 - Measuring or testing processes involving enzymes, nucleic acids or microorganismsCompositions thereforProcesses of preparing such compositions involving nucleic acids
A61K 39/00 - Medicinal preparations containing antigens or antibodies
